ArticleFrontiers in pharmacology2017
Neurologically Potent Molecules from
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 84 citations in OpenAlex.
- Review
- Machine Learning-Integrated Pharmacophore, DFT Analysis, and molecular dynamics of Diosmetin as a potent ache inhibitor with neuroprotective activity in a Scopolamine-Induced alzheimer's zebrafish model.Journal of computer-aided molecular design · 2026Article
- A Review on Hepatoprotective Effect of Chrysin: Preclinical Implications and Molecular Cascades Came into Focus.Current diabetes reviews · 2026Review
- Combined exercise and Hawthorn protect against learning impairments and hippocampal damage from trimethyltin neurotoxicity in rat.Scientific reports · 2025Article
- Assessment of antibacterial, nematicidal and herbicidal activities of Cautleya spicata (Sm.) Baker extracts, with chemical profiling using GC-MS.Scientific reports · 2025Article
- Unveiling the Potential Neuroprotective Effect of Bioactive Compounds from Plants with Sedative and Mood-Modulating Properties: Innovative Approaches for the Prevention of Alzheimer's and Parkinson's Diseases.Current neuropharmacology · 2025Review
- Chemo- and bio-informatics insight into anti-cholinesterase potentials of berries and leaves of Myrtus communis L., Myrtaceae: an in vitro/in silico study.BMC complementary medicine and therapies · 2023Article
- A Triterpenoid Lupeol as an Antioxidant and Anti-Neuroinflammatory Agent: Impacts on Oxidative Stress in Alzheimer's Disease.Nutrients · 2023Review
- Molecular Mechanisms of the Protective Effects of Olive Leaf Polyphenols against Alzheimer's Disease.International journal of molecular sciences · 2023Review
- In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.Molecules (Basel, Switzerland) · 2022Article
- Succinimide Derivatives as Antioxidant Anticholinesterases, Anti-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.Frontiers in neuroscience · 2022Review
- Botanical, Phytochemical, Anti-Microbial and Pharmaceutical Characteristics of Hawthorn (Molecules (Basel, Switzerland) · 2021Review
- RETRACTED: Deciphering the Potential Neuroprotective Effects of Luteolin against AβInternational journal of molecular sciences · 2021Article
- Green-synthesized zinc oxide nanoparticles, anti-Alzheimer potential and the metabolic profiling ofRSC advances · 2021Article
- Evaluation of Antioxidant and Enzyme Inhibition Properties ofMolecules (Basel, Switzerland) · 2021Article
- In vitro cholinesterase inhibitory action ofIn silico pharmacology · 2021Article
- Himalayan NettleMolecules (Basel, Switzerland) · 2020Article
- Article
- Neuroprotective Studies onFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.